Neuroinflammation Assay Services for Alzheimer’s Disease R&D
At Ace Therapeutics, we recognize that neuroinflammation is not just a bystander in Alzheimer's disease (AD)—it's a driving force behind neurodegeneration. Our preclinical neuroinflammation assays are designed to dissect the complex interplay between microglia, astrocytes, and neurons, helping you identify compounds that modulate inflammatory pathways without compromising neuroprotection.
Neuroinflammation in Alzheimer's involves dysregulated microglial activation, astrocyte reactivity, and cytokine storms that exacerbate amyloid-beta (Aβ) and tau pathology. Traditional models often overlook human-specific immune responses, leading to failed translation. Our assays address this by
Human-relevant systems to study AD-specific inflammation.
Evaluate compound effects on key inflammatory pathways.
Capture dynamic inflammatory responses at single-cell resolution.
Tailored solutions for your therapeutic strategy.
At Ace Therapeutics, we deploy cutting-edge tools to unravel the complexities of neuroinflammation in Alzheimer's disease—where microglial overactivation, cytokine storms, and impaired phagocytosis converge. Our technologies are engineered to mirror human-specific inflammatory cascades, from NLRP3 inflammasome dynamics to TREM2-dependent signaling. Below, explore the platforms that power our assays, combining scalability, precision, and translational relevance to transform your preclinical neuroinflammation research.
| Technology | Application |
| CRISPR-edited TREM2 models | Study AD risk variants (e.g., R47H) in microglial function and phagocytosis. |
| Organ-on-chip neurovascular units | Model BBB-immune interactions in neuroinflammatory environments. |
| High-content imaging (HCI) | Track microglial migration and chemotaxis in real time. |
| Spatial transcriptomics | Map cytokine expression gradients in 3D spheroids. |
Neuroinflammation is a double-edged sword in Alzheimer's—too little impedes plaque clearance, too much accelerates neurodegeneration. Ace Therapeutics equips you with the tools to strike the right balance. Contact us today to design a preclinical strategy that turns your anti-inflammatory candidate into a disease-modifying therapy.
What cell types do you support for neuroinflammation studies
We offer iPSC-derived microglia, astrocytes, and neurons, as well as primary rodent microglia. Custom co-cultures (e.g., neuron-microglia-astrocyte) are available.
Can you profile compounds targeting the NLRP3 inflammasome
Yes. Our assays measure caspase-1 activation, IL-1β release, and ASC speck formation in Aβ-stimulated models.
How much compound is required for screening
Most HTS assays require 1–5 mg for small molecules or 0.5–2 mg for biologics. Microscale options reduce material needs by 50%.
Do you provide data on reactive astrocytes (A1 vs A2)
Absolutely. We use RNA-seq and protein markers (C3, PTX3) to classify astrocyte polarization states.
What turnaround times can I expect
High-throughput screens take 3–4 weeks. Custom 3D spheroid or organ-on-chip studies require 6–8 weeks.
Our products and services are for research use only and can not be used for diagnostic or other purposes.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a specialized team of scientists and technical professionals committed to working closely with clients worldwide. We offer comprehensive preclinical testing solutions to support the development of novel therapies and medications across a range of disease areas.
Ace Therapeutics boasts a team of highly committed and skilled researchers dedicated to delivering innovative preclinical contract research solutions.
We provide tailored preclinical services designed to streamline your research process and advance promising concepts into actionable insights, ensuring efficient progress in drug development.